Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR: HG004 Gene Therapy for RPE65-associated LCA2
NCT05906953Phase 2Recruiting
- Sponsor
- HuidaGene Therapeutics
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of HG004 in Leber congenital amaurosis (LCA), sponsored by HuidaGene Therapeutics. Started Oct 2023; status: recruiting.
02
Drugs
HG004
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT05906953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906953.